Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Shares Outstanding (Diluted Average) (2019 - 2024)

Historic Shares Outstanding (Diluted Average) for Ptc Therapeutics (PTCT) over the last 6 years, with Q4 2024 value amounting to $76.8 million.

  • Ptc Therapeutics' Shares Outstanding (Diluted Average) rose 268.13% to $76.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $76.8 million, marking a year-over-year increase of 268.13%. This contributed to the annual value of $76.8 million for FY2024, which is 268.13% up from last year.
  • As of Q4 2024, Ptc Therapeutics' Shares Outstanding (Diluted Average) stood at $76.8 million, which was up 268.13% from $76.9 million recorded in Q3 2024.
  • Ptc Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $76.9 million during Q3 2024, with a 5-year trough of $66.0 million in Q4 2020.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $72.9 million, with a median of $71.7 million in 2022.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 1217.18% in 2020, then surged by 136.1% in 2022.
  • Over the past 5 years, Ptc Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $66.0 million in 2020, then rose by 6.72% to $70.5 million in 2021, then grew by 1.79% to $71.7 million in 2022, then increased by 4.34% to $74.8 million in 2023, then grew by 2.68% to $76.8 million in 2024.
  • Its Shares Outstanding (Diluted Average) stands at $76.8 million for Q4 2024, versus $76.9 million for Q3 2024 and $76.7 million for Q2 2024.